Givlaari Shortage Update: What Patients Need to Know in 2026

If you've been searching for information about a Givlaari shortage, you are not alone. Patients and caregivers across the country have reported difficulty obtaining their monthly doses of Givlaari (givosiran), and questions about availability are among the most common we receive at medfinder. Here is a clear-eyed look at what is actually happening in 2026.

Is Givlaari Officially in Shortage?

As of 2026, Givlaari (givosiran) is not listed on the FDA's official drug shortage database. The FDA's shortage list typically reflects manufacturing supply disruptions — situations where a drug maker cannot produce enough drug to meet demand.

However, the absence of an official shortage does not mean patients have easy access. For Givlaari, the access challenges are structural rather than supply-related. The medication is being manufactured. Getting it to patients reliably is where the system breaks down.

What Is Causing Givlaari Access Problems?

The barriers are layered and compounding:

• Prior authorization delays: Every major insurer requires prior authorization for Givlaari. Standard reviews take 15-30 days; denials and appeals can add months.
• Step therapy requirements: Many insurers require documentation of prior hemin therapy before approving Givlaari, forcing patients to navigate an additional hurdle even when their specialist has already recommended it.
• Limited distribution network: Givlaari is only available through CVS Specialty and Accredo. Not every clinical site is enrolled in the distribution network, limiting where patients can receive their injections.
• Extreme cost: At approximately $575,000 per year, Givlaari is among the costliest drugs in the U.S., making uninsured or underinsured access essentially impossible without manufacturer assistance.
• Small specialist network: AHP is a rare disease. Porphyria specialists who can diagnose it, manage it, and order Givlaari are concentrated at academic medical centers. Patients in rural areas may wait months for a specialist appointment.

Givlaari's History: A Landmark Approval

Givlaari was approved by the FDA on November 20, 2019. It received Breakthrough Therapy designation, Priority Review, and Orphan Drug designation — all reflecting the serious unmet medical need in AHP. Before Givlaari, the main treatment option for preventing attacks was prophylactic hemin infusions (off-label) or suffering through attacks treated with IV hemin. Givlaari was the first disease-modifying therapy that targets the root cause of AHP attacks — ALAS1 overexpression in the liver.

In clinical trials (ENVISION), Givlaari reduced porphyria attacks by approximately 70% compared to placebo. Long-term follow-up data at 36 months confirmed sustained reduction in attacks and ALA/PBG levels. In the final three months of the 36-month open-label extension, 86-96% of patients experienced zero attacks.

Annual Renewal: An Ongoing Access Risk

Insurance coverage for Givlaari requires annual renewal. UnitedHealthcare, Aetna, Humana, Cigna, and most other major insurers require patients to demonstrate ongoing clinical benefit to continue coverage. Renewals typically require updated ALA/PBG lab values every 3-6 months and documentation of reduced attack frequency. Lapses in renewal paperwork can cause gaps in coverage — which translate directly into missed doses.

What Patients Should Do Right Now

1. Don't wait for renewal to expire: Start the renewal process 30-90 days before your current prior authorization expires.
2. Maintain your monitoring labs: Keep ALA/PBG labs and liver/kidney function tests current. These are required for renewal.
3. Contact Alnylam Assist®: If there is any gap in coverage, call 1-833-256-2748 immediately. The Bridge Program can provide Givlaari at no cost while authorization is pending.
4. Use medfinder: medfinder contacts specialty pharmacies and clinical sites on your behalf to find out which ones can fill and administer your prescription — saving you time during urgent situations.

The Bottom Line

Givlaari is not in an official FDA shortage, but the access challenges patients face are real and significant. They are caused by cost, insurance barriers, a limited distribution network, and a small specialist base — not a manufacturing supply problem. Being proactive about renewals, using manufacturer support programs, and utilizing tools like medfinder can significantly reduce the risk of gaps. See also our guide on how to save money on Givlaari for financial assistance options.